Navigation Links
Newly appreciated membrane estrogen receptor important therapeutic target for breast cancer
Date:7/1/2009

PROVIDENCE, RI New research at Rhode Island Hospital has uncovered the biological effects of a novel membrane estrogen receptor, a finding that has potential implications for hormonal therapy for breast cancer. The study is published in the July edition of the journal Molecular Endocrinology. This new study by Edward Filardo, MD, and his research team further supports earlier published work by the group that linked the transmembrane receptor, GPR30/GPER-1, to specific estrogen binding, rapid estrogen signaling and breast cancer metastasis. "What is exciting about this new work," says Filardo, "is that it provides some insight into the influence of GPR30 at the cellular level. It shows that estrogen action through GPR30 allows for breast tumor cell survival, and not breast tumor cell proliferation." Prior studies by Filardo's group showed that estrogen acts through GPR30 to promote the rapid release of preformed growth factors that are tethered to the surface of breast cancer cells. Their latest study was conducted in an effort to better understand the mechanism by which GPR30 triggered the release of epidermal growth factor (EGF) polypeptides from the surface of breast cancer cells.

The investigator's found that the "growth factors" did not promote cellular growth, which by itself is not a novel finding. It has long been appreciated that EGF-related factors are also important in other cellular activities such as cellular survival. Filardo and the research team, however, found that estrogen action through GPR30 had a more profound effect on tumor cell survival. They found that GPR30 promoted the assembly of what is called a "provisional extracellular matrix" -- a crucial event in cellular survival. More specifically, they found that release of growth factor by GPR30 required the activation of a latent adhesion receptor (known as integrin 51).

Filardo says, "Activation of integrin 51 by GPR30 is a significant event because it provides a way for invading cells to gain hold once they metastasize to tissues distant to the primary breast cancer. This happens because activated integrin 51 can convert soluble plasma protein fibronectin into an insoluble cage. The breast cancer cells can use this to adapt to a new environment."

In general, about two-thirds of all breast cancer cases involve tumors that retain expression of estrogen receptors (ER). They are presumed to proliferate in response to estrogen produced by the patient. Consequently, patients with ER-positive tumors receive hormonal agents (known as ER antagonists) that act by blocking the proliferative effects of estrogen promoted by the ER. As a result, the capacity of breast cancers to grow is reduced. The development of new drugs targeting GPR30 may be an important step in controlling breast cancer because this newly appreciated estrogen receptor is not promoting estrogen-dependent growth but may be critical in promoting breast tumor cell survival.

Filardo says, "There has been a recent shift toward treating ER-positive breast tumor patients with aromatase inhibitors such as tamoxifen that block estrogen biosynthesis. The thought is that this is yet another way to prevent estrogen from acting as its sole receptor, the ER." He concludes, "The discovery that GPR30 represents yet another estrogen receptor with biological significance for breast cancer furthers the argument that aromatase inhibitors would effectively block estrogen action at both types of estrogen receptors."


'/>"/>

Contact: Nancy Cawley Jean
njean@lifespan.org
Lifespan
Source:Eurekalert

Related medicine news :

1. Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network
2. Dr. Juan Carlos Cobo Newly-Elected Chair of the Mutual Protection Trust Board of Trustees
3. Missouri Doctor, David Barbe, M.D., Newly Elected to AMA Board of Trustees
4. kidneySPA Introduces A Revolutionary Approach To Dialysis Treatment Newly Opened Facility Combines "Medical" Expertise with "Spa-Like" Experience
5. Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug
6. Newly Identified Compounds May Inhibit Strep Infection
7. Now we know what blocks the effects of a newly developed anticancer therapy
8. Brockton Mayor, James E. Harrington Calls Press Conference to Unveil Newly Adopted Auto Emissions Technology Acquired With Federal Stimulus Money
9. MAXANT Launches MediPort 3000, The Next-Generation of All-In-One Workstations, on Its Newly Designed Website
10. Discount Medical Supplies Superstore Announces Newly Updated Website: Easy Shopping, Hundreds of Top Brands
11. Walnuts and Fish Protect Against Heart Disease in Different Ways, According to Newly Published Loma Linda University Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... SANTA CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... government and financial organizations, today announced it has partnered with WALLIX to ... NIST Special Publication 800-171 . , There are a number of ways to address ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know they ... would a pharmacist using that same scale to dispense medication. The first example is ... These illustrations show why it is important to have the right balance for the ...
(Date:7/24/2017)... ... 24, 2017 , ... A Southern California-based author has released a new book ... she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. Madsen, highlights ... risen above. , In “Memories,” readers get a firsthand look at what Michelle has ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... how to change manufacturers future. , The agency is hammering out a game ... one of the farthest-ranging laws ever to affect FDA-regulated firms. The new law:, ...
(Date:7/24/2017)... ... 24, 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir ... of published author, Ed Clark. Ed Clark is a church music director and ... a minister of music and worship leader for over fifty years. He has ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
(Date:6/30/2017)... -- AVACEN Medical (AVACEN) announced the publication of new research in the ... its AVACEN Treatment Method to significantly reduce the widespread ... ... ... approximately 200 to 400 million people worldwide according to The National ...
Breaking Medicine Technology: